[Stimulating and hypobiotic therapy in cardiogenic shock]

Area of Science:

• Cardiology
• Veterinary Medicine
• Pharmacology

Background:

• Cardiogenic shock is a critical condition in both dogs and humans.
• Acute myocardial infarction can lead to life-threatening cardiogenic shock.
• Effective therapeutic strategies are crucial for managing this complex pathology.

Purpose of the Study:

• To comparatively evaluate the efficacy of stimulating and hypobiotic agents.
• To establish a relationship between therapeutic efficiency and the progression rate of cardiogenic shock.
• To guide the selection of appropriate treatments based on disease dynamics.

Main Methods:

• Experimental induction of cardiogenic shock in 122 dogs.
• Study of 56 human patients with acute myocardial infarction and cardiogenic shock.
• Comparative analysis of stimulating and hypobiotic therapeutic agents.

Main Results:

• Treatment efficacy is directly related to the phase and progression rate of the pathological process.
• Hypobiotic agents are predominantly prescribed for rapidly progressing clinical symptoms of cardiogenic shock.
• Stimulating agents are advisable for slowly progressing cases of cardiogenic shock.

Conclusions:

• The choice between stimulating and hypobiotic agents should be guided by the rate of disease progression.
• Tailoring therapy based on disease dynamics can optimize outcomes in cardiogenic shock.
• This study provides evidence-based recommendations for managing cardiogenic shock in both veterinary and human medicine.